Bendamustine | List of Frontiers open access articles

Original Research

Published on 13 May 2024

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database

in Pharmacoepidemiology

Dan Li
Yuan Zhang
Jia Qi Ni
Juan Zhu
Wen Ting Lu
Ya Lin Chen
Lei Cheng
Yu Qi Wang
Qian Jiang Li
Jie Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1372401

5,621 views
4 citations

Original Research

Published on 31 Jul 2023

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

in Cancer Immunity and Immunotherapy

Patrick Greve
Auke Beishuizen
Melanie Hagleitner
Jan Loeffen
Margreet Veening
Marianne Boes
Victor Peperzak
Claudius Diez
Friederike Meyer-Wentrup

Frontiers in Immunology

doi 10.3389/fimmu.2023.1229558

6,936 views
7 citations

Case Report

Published on 09 Oct 2025

Case Report: Severe neutropenia induced by avelumab in a patient with Merkel cell carcinoma

in Cancer Immunity and Immunotherapy

Eri Ohta
Kayo Yamamoto
Hitomi Fujimura
Natsuko Saito-Sasaki
Etsuko Okada
Yu Sawada

Frontiers in Immunology

doi 10.3389/fimmu.2025.1672282

1,313 views
1 citation

Original Research

Published on 01 Dec 2023

Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients

in Immunological Memory

Anna Vanni
Lorenzo Salvati
Alessio Mazzoni
Giulia Lamacchia
Manuela Capone
Stefania Francalanci
Seble Tekle Kiros
Lorenzo Cosmi
Benedetta Puccini
Manuel Ciceri

Frontiers in Immunology

doi 10.3389/fimmu.2023.1322594

3,863 views
10 citations

Case Report

Published on 03 Oct 2025

Iptacopan for cold agglutinin disease: a case report with literature review

in Cancer Immunity and Immunotherapy

Baozhi Fang
Hongbin Lu
Xiao Yu
Peng Wang
Yifei Zhou
Qiudan Shen
Muzhi Yuan
Mingen Lyu
Guangsheng He

Frontiers in Immunology

doi 10.3389/fimmu.2025.1672590

2,551 views

Case Report

Accepted on 27 Jan 2026

Uncommon Presentation of T-Cell Prolymphocytic Leukemia: A Case with Secondary Autoimmune Hemolytic Anemia

in Hematology

Xiufeng WANG
Ting LI
Linlin TIAN
Man YANG
Fengli LI
Sun WU
Yan HUANG

Frontiers in Medicine

131 views

Original Research

Published on 29 Jun 2017

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

in Cancer Molecular Targets and Therapeutics

Sara Galimberti
Elena Ciabatti
Giacomo Ercolano
Susanna Grassi
Francesca Guerrini
Nadia Cecconi
Martina Rousseau
Giulia Cervetti
Francesco Mazziotta
Lorenzo Iovino

Frontiers in Pharmacology

doi 10.3389/fphar.2017.00413

6,257 views
4 citations

Case Report

Published on 18 Aug 2025

Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review

in Hematologic Malignancies

Junjun Bai
Yi Zhang
Kangqi Lv
Bei Zhang
Hongxia Wang
Zhixin Pei
Yingxin Zhao
Jingjing Gu
Huimin Wu
Qinglin Song

Frontiers in Oncology

doi 10.3389/fonc.2025.1635856

1,855 views

Case Report

Published on 10 Jan 2022

Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine

in Cancer Immunity and Immunotherapy

Ramon Diez-Feijóo
Juan Jose Rodríguez-Sevilla
Concepcion Fernández-Rodríguez
Solange Flores
Carmen Raya
Ana Ferrer
Luis Colomo
Antonio Salar

Frontiers in Immunology

doi 10.3389/fimmu.2021.798251

5,703 views
5 citations

Original Research

Published on 16 Jul 2020

Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3

in Alloimmunity and Transplantation

Megan S. Molina
Jessica Stokes
Emely A. Hoffman
Jelena Eremija
Yi Zeng
Richard J. Simpson
Emmanuel Katsanis

Frontiers in Immunology

doi 10.3389/fimmu.2020.01410

4,899 views
13 citations

Original Research

Published on 24 Jun 2021

Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death

in Immunological Tolerance and Regulation

Megan S. Molina
Emely A. Hoffman
Jessica Stokes
Nicole Kummet
Kyle A. Smith
Forrest Baker
Tiffany M. Zúñiga
Richard J. Simpson
Emmanuel Katsanis

Frontiers in Immunology

doi 10.3389/fimmu.2021.699128

6,946 views
17 citations

Original Research

Published on 18 Feb 2025

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

in Pharmacoepidemiology

Fang Wu
Siliang Wang
Xihui Xu
Weihui Zhang
Jie Zhou
Runyan Niu
Wenting Cai
Yonggong Yang
Mengying Liu
Jinping Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1459067

4,148 views
1 citation

Mini Review

Published on 14 May 2021

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

in Hematologic Malignancies

Hussein A. Abbas
William G. Wierda

Frontiers in Oncology

doi 10.3389/fonc.2021.668162

17,872 views
45 citations

Brief Research Report

Published on 20 Mar 2023

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

in Molecular and Cellular Oncology

Valeria J. Sarapura Martinez
Brenda Buonincontro
Chiara Cassarino
Juliana Bernatowiez
Ana Colado
Gregorio Cordini
Maria del Rosario Custidiano
Carolina Mahuad
Miguel A. Pavlovsky
Raimundo F. Bezares

Frontiers in Oncology

doi 10.3389/fonc.2023.1143881

4,768 views
6 citations

Original Research

Published on 09 Jan 2023

Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease

in Alloimmunity and Transplantation

Kristy E. Gilman
Megan J. Cracchiolo
Andrew P. Matiatos
Dan W. Davini
Richard J. Simpson
Emmanuel Katsanis

Frontiers in Immunology

doi 10.3389/fimmu.2022.1045710

4,032 views
3 citations

Original Research

Published on 05 Nov 2025

Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era

in Hematologic Malignancies

Akinao Okamoto
Masahiro Yoshida
Senji Kasahara
Takahide Ara
Kazutaka Ozeki
Takanobu Morishita
Daisuke Ikeda
Minoru Kanaya
Tomohiro Kajiguchi
Yasuhiro Suzuki

Frontiers in Oncology

doi 10.3389/fonc.2025.1687204

2,000 views

Articles

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Case Report: Severe neutropenia induced by avelumab in a patient with Merkel cell carcinoma

Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients

Iptacopan for cold agglutinin disease: a case report with literature review

Uncommon Presentation of T-Cell Prolymphocytic Leukemia: A Case with Secondary Autoimmune Hemolytic Anemia

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review

Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine

Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3

Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease

Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era